Review

egf (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems egf
Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 123 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+egf+quantikine+elisa+kit/Human+EGF+Quantikine+ELISA+Kit/pmc12968418-47-76-79
Average 95 stars, based on 123 article reviews

egf - by Bioz Stars, 2026-10

95/100 stars

Images

Enzyme-linked Immunosorbent Assay:

Article Title: Mammary Microvessels are Sensitive to Menstrual Cycle Sex Hormones.
Article Snippet: The blots were visualized and imaged (1 min exposure) using the Fusion FX Spectra (Vilber, France). .. ELISA Assay: Quantification of ET-1, VEGF, bFGF, PLGF, and EGF in the media collected from each device (N = 3 with 3 devices per experiment) was performed respectively with ELISA assay Human Endothelin1 Quantikine ELISA kit (R&D Systems, DET100): Human VEGF Quantikine ELISA Kit (R&D Systems, DVE00), Human FGF basic/FGF2/bFGF Quantikine Kit (R&D Systems, DFB50), Human PlGF Quantikine ELISA Kit (R&D Systems, DPG00), and Human EGF Quantikine ELISA Kit (R&D Systems, DEG00) according to manufacturer’s instructions. ..

Article Title: Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy.
Article Snippet: L-FABP was measured by ELISA from Bio-Rad (Hercules, CA, USA). .. KIM-1 and DKK-3 were quantified using ELISA kits from R&D Systems (Minneapolis, USA), MCP-1 and NGAL were measured by an ELISA from Abcam (Cambridge, UK); β2-microglobulin was measured by immunoturbidimetry (Pacific Biomarkers, Seattle, USA); EGF urine excretion was measured by an ELISA assay (Human EGF Quantikine ELISA Kit, R&D Systems, Minneapolis, MN, USA). ..

Article Title: Inhibition of oxidative stress-induced epithelial-mesenchymal transition in retinal pigment epithelial cells of age-related macular degeneration model by suppressing ERK activation.
Article Snippet: All samples were assayed in triplicate for CCK-8 and LDH content at a wavelength of 450 nm (CCK-8) and 490 nm (LDH) using a Sunrise microplate reader (Tecan, Männedorf, Switzerland). .. ELISA measurement of BMP4, TGF-b1, and EGF secretion levels Human BMP4 ELISA kit (#E-EL-H0012; Elabscience, Wuhan, China), human TGF-b1 Quantikine ELISA kit (#DB100B; R&D Systems, Minneapolis, MN, USA), and human EGF Quantikine ELISA kit (#DEG00; R&D Systems, Minneapolis, MN, USA) were used according to the manufacturer’s instructions. .. The reactions were quantified by optical density measurement using a Sunrise automated ELISA reader (Tecan).

Article Title: Intraindividual variations of urinary biomarkers in hospitalized children with glomerular diseases: a prospective observational study.
Article Snippet: .. Urinary EGF was measured with the Human EGF Quantikine ELISA Kit (SEG00, R&D Systems, USA) respectively. ..

Article Title: Mammary Microvessels are Sensitive to Menstrual Cycle Sex Hormones
Article Snippet: The blots were visualized and imaged (1 min exposure) using the Fusion FX Spectra (Vilber, France). .. Quantification of ET‐1, VEGF, bFGF, PLGF, and EGF in the media collected from each device ( N = 3 with 3 devices per experiment) was performed respectively with ELISA assay Human Endothelin‐1 Quantikine ELISA kit (R&D Systems, DET100): Human VEGF Quantikine ELISA Kit (R&D Systems, DVE00), Human FGF basic/FGF2/bFGF Quantikine Kit (R&D Systems, DFB50), Human PlGF Quantikine ELISA Kit (R&D Systems, DPG00), and Human EGF Quantikine ELISA Kit (R&D Systems, DEG00) according to manufacturer's instructions. ..

Article Title: Inhibition of oxidative stress-induced epithelial-mesenchymal transition in retinal pigment epithelial cells of age-related macular degeneration model by suppressing ERK activation
Article Snippet: All samples were assayed in triplicate for CCK-8 and LDH content at a wavelength of 450 nm (CCK-8) and 490 nm (LDH) using a Sunrise microplate reader (Tecan, Männedorf, Switzerland). .. Human BMP4 ELISA kit (#E-EL-H0012; Elabscience, Wuhan, China), human TGF-β1 Quantikine ELISA kit (#DB100B; R&D Systems, Minneapolis, MN, USA), and human EGF Quantikine ELISA kit (#DEG00; R&D Systems, Minneapolis, MN, USA) were used according to the manufacturer’s instructions. .. The reactions were quantified by optical density measurement using a Sunrise automated ELISA reader (Tecan).

Article Title: Human-Derived Low-Molecular-Weight Protamine (hLMWP) Conjugates Enhance Skin Cell Penetration and Physiological Activity
Article Snippet: .. A sample was collected from the receiving chamber of the static diffusion device and quantitative analysis was performed by measuring the concentration of the transmitted protein using the Human EGF Quantikine ELISA Kit (R&D system, Minneapolis, MN, USA, DEG00) and the Human Superoxide Dismutase 1 ELISA kit (Abcam, Cambridge, UK, ab119520). .. Statistical analysis of the experimental data points was performed by ANOVA and Duncan’s multiple range test using SPSS software (version 22.0; IBM, Armonk, Chicago, IL, USA) and Student’s t-test. p < 0.05 was considered statistically significant.

Article Title: Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy
Article Snippet: L-FABP was measured by ELISA from Bio-Rad (Hercules, CA, USA). .. KIM-1 and DKK-3 were quantified using ELISA kits from R&D Systems (Minneapolis, USA), MCP-1 and NGAL were measured by an ELISA from Abcam (Cambridge, UK); β2-microglobulin was measured by immunoturbidimetry (Pacific Biomarkers, Seattle, USA); EGF urine excretion was measured by an ELISA assay (Human EGF Quantikine ELISA Kit, R&D Systems, Minneapolis, MN, USA). ..

Diffusion-based Assay:

Concentration Assay:

Image Search Results

Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human endothelial cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor (VEGF; 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human endothelial cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor (VEGF; 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).

Article Snippet: NAV2729 and Secin H3 were purchased from Tocris Bioscience (Abingdon, UK); Proteome Profiler Human angiogenesis array and enzyme-linked immunosorbent assay (ELISA) kits for human angiopoietin-2 (DANG20), endothelial growth factor (EGF; DEG00), endoglin (DNDG00), placental growth factor (PIGF; DPG00), prolactin (DY682), and vascular endothelial growth factor (VEGF; DVE00) were all obtained from R&D Systems (Abingdon, UK).

Techniques: MTT Assay, Control, Migration, Wound Healing Assay

Nicotine-free eVape exposure causes significant upregulation of angiopoietin-2, endoglin, placental growth factor (PIGF), and VEGF as well as significant downregulation of endothelial growth factor (EGF) and prolactin in endothelial cells. HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h. (a–c) Cell lysates were used for the Proteome Profiler Angiogenesis array membranes. Changes in the expression of all angiogenesis-related proteins in array (a) (ii) were quantified using the membranes (representative image in (a) (i) ). Specific analyses of the (b) upregulation and (c) downregulation of angiogenesis-related proteins on the membranes were quantified. (d) mRNA expression of angiopoietin-2, EGF, endoglin, PIGF, prolactin, and VEGF were measured by RT-PCR using specific primers. (e) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays. The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Nicotine-free eVape exposure causes significant upregulation of angiopoietin-2, endoglin, placental growth factor (PIGF), and VEGF as well as significant downregulation of endothelial growth factor (EGF) and prolactin in endothelial cells. HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h. (a–c) Cell lysates were used for the Proteome Profiler Angiogenesis array membranes. Changes in the expression of all angiogenesis-related proteins in array (a) (ii) were quantified using the membranes (representative image in (a) (i) ). Specific analyses of the (b) upregulation and (c) downregulation of angiogenesis-related proteins on the membranes were quantified. (d) mRNA expression of angiopoietin-2, EGF, endoglin, PIGF, prolactin, and VEGF were measured by RT-PCR using specific primers. (e) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays. The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay

Activation of ARF6 by its guanine nucleotide exchange factor (ARNO) regulates angiogenic processes in endothelial cells induced by nicotine-free eVape. (a, b) HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h, and the cell lysates were analysed by Western blotting for (a) ARF6 or (b) ARNO expression. The Western blotting membranes (representative blots are shown in (i) ) were quantified and normalised to the actin expression shown in (ii) . (c–f) HUVECs were treated with ARF6 inhibitor (NAV2729; 5 µM), ARNO inhibitor (Secin H3; 10 µM), or dimethyl sulfoxide (DMSO) as vehicle control at the same time as eVape exposure. (c) ROS accumulation was assessed by DCFDA incorporation (fluorescence at 485/535 nm) following 2 h of treatment. (d) Cell adhesion, (e) migration, and (f) angiogenic potential were measured following (d, e) 6 h and (f) 24 h of treatments. (g) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays following 24 h of treatment with 2% nicotine-free eVape fluid in the presence (closed circles) and absence (open circles) of Secin H3 (10 µM). The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for NAV2729 and Secin H3 (DMSO).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Activation of ARF6 by its guanine nucleotide exchange factor (ARNO) regulates angiogenic processes in endothelial cells induced by nicotine-free eVape. (a, b) HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h, and the cell lysates were analysed by Western blotting for (a) ARF6 or (b) ARNO expression. The Western blotting membranes (representative blots are shown in (i) ) were quantified and normalised to the actin expression shown in (ii) . (c–f) HUVECs were treated with ARF6 inhibitor (NAV2729; 5 µM), ARNO inhibitor (Secin H3; 10 µM), or dimethyl sulfoxide (DMSO) as vehicle control at the same time as eVape exposure. (c) ROS accumulation was assessed by DCFDA incorporation (fluorescence at 485/535 nm) following 2 h of treatment. (d) Cell adhesion, (e) migration, and (f) angiogenic potential were measured following (d, e) 6 h and (f) 24 h of treatments. (g) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays following 24 h of treatment with 2% nicotine-free eVape fluid in the presence (closed circles) and absence (open circles) of Secin H3 (10 µM). The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for NAV2729 and Secin H3 (DMSO).

Techniques: Activation Assay, Western Blot, Expressing, Control, Fluorescence, Migration, Enzyme-linked Immunosorbent Assay

Senescent conditioned media (CM) promote growth of A549 cells through SASP factor EGF1. (a) Growth promotion of A549 cells by senescent CM compared to control CM of human pulmonary fibroblasts – adult (HPF-a). Cells were seeded at a density of 25,000 cells per well in a 24-well plate the day before treated with indicated CM. Real-time cell growth was monitored using IncuCyte® SX5 Live-Cell Analysis Instrument (Sartorius AG) for 3-5 days. Cell growth was analysed using the IncuCyte® software and manifested as percentage over the baseline confluence. Data of 6 biological replicates are shown as mean ± SD. **indicates significant difference (p<0.01) from cells treated with Ctrl CM as determined by ANOVA analysis. (b-c) Secretome analysis of CM from control or senescent HPF-a. CM were harvested after 72-h incubation with corresponding HPF-a and the components were evaluated using Proteome Profiler Human XL Cytokine Array kit (#ARY022B, R&D Systems). VCAM-1, vascular cell adhesion molecule 1. The original blots (b) and quantification results are shown as heatmap (c) . (d) Validation of EGF1 level in CM with ELISA. The CM were harvested and subjected to ELISA (#DEG00, R&D Systems) for determining the amounts of EGF1 with normalization based on cell contents. Data of 6 biological replicates are shown as mean ± SD. *p < 0.05; ** p < 0.01 as determined by ANOVA analysis. ns, not statistically significant. (e) Reversion of CM-enhanced cell growth by EGF receptor blocker gefitinib (Gef). A549 cells were cotreated with CM from control or senescent HPF-a with or without gefitinib (2.5 μM) before subjected to IncuCyte® SX5 Live-Cell Analysis Instrument (Sartorius AG) for 3-5 days. Representative data of 3 independent biological repeats are shown as mean ± SD. **** p < 0.0001 as determined by ANOVA analysis. (f-h) Reversion of CM-enhanced colony formation by EGF receptor blocker gefitinib (Gef). A549 cells were seeded at a density of 750 cells per well in a 6-well plate the day before treatment with designated HPF-a CM and/or gefitinib for 15 days. Treatment was refreshed every 2-3 days. Colonies were stained with crystal violet and images were scanned for quantification as described in the methodology. Representative images (f) , colony count (g) , and OD595 (h) of 3-4 independent biological replicates are shown as mean ± SD. *p < 0.05; ** p < 0.01; *** p < 0.001 as determined by ANOVA analysis.

Journal: bioRxiv

Article Title: Identification of senescence-associated drivers of tumour growth and progression using a novel microarray platform

doi: 10.64898/2025.12.20.695739

Figure Lengend Snippet: Senescent conditioned media (CM) promote growth of A549 cells through SASP factor EGF1. (a) Growth promotion of A549 cells by senescent CM compared to control CM of human pulmonary fibroblasts – adult (HPF-a). Cells were seeded at a density of 25,000 cells per well in a 24-well plate the day before treated with indicated CM. Real-time cell growth was monitored using IncuCyte® SX5 Live-Cell Analysis Instrument (Sartorius AG) for 3-5 days. Cell growth was analysed using the IncuCyte® software and manifested as percentage over the baseline confluence. Data of 6 biological replicates are shown as mean ± SD. **indicates significant difference (p<0.01) from cells treated with Ctrl CM as determined by ANOVA analysis. (b-c) Secretome analysis of CM from control or senescent HPF-a. CM were harvested after 72-h incubation with corresponding HPF-a and the components were evaluated using Proteome Profiler Human XL Cytokine Array kit (#ARY022B, R&D Systems). VCAM-1, vascular cell adhesion molecule 1. The original blots (b) and quantification results are shown as heatmap (c) . (d) Validation of EGF1 level in CM with ELISA. The CM were harvested and subjected to ELISA (#DEG00, R&D Systems) for determining the amounts of EGF1 with normalization based on cell contents. Data of 6 biological replicates are shown as mean ± SD. *p < 0.05; ** p < 0.01 as determined by ANOVA analysis. ns, not statistically significant. (e) Reversion of CM-enhanced cell growth by EGF receptor blocker gefitinib (Gef). A549 cells were cotreated with CM from control or senescent HPF-a with or without gefitinib (2.5 μM) before subjected to IncuCyte® SX5 Live-Cell Analysis Instrument (Sartorius AG) for 3-5 days. Representative data of 3 independent biological repeats are shown as mean ± SD. **** p < 0.0001 as determined by ANOVA analysis. (f-h) Reversion of CM-enhanced colony formation by EGF receptor blocker gefitinib (Gef). A549 cells were seeded at a density of 750 cells per well in a 6-well plate the day before treatment with designated HPF-a CM and/or gefitinib for 15 days. Treatment was refreshed every 2-3 days. Colonies were stained with crystal violet and images were scanned for quantification as described in the methodology. Representative images (f) , colony count (g) , and OD595 (h) of 3-4 independent biological replicates are shown as mean ± SD. *p < 0.05; ** p < 0.01; *** p < 0.001 as determined by ANOVA analysis.

Article Snippet: For evaluating specific secretomes, ELISA kits were used for determining the amounts of EGF1(#DEG00, R&D Systems) or TGF-β1 (#DB100C, R&D Systems) in indicated CM with normalization based on cell content.

Techniques: Control, Cell Analysis, Software, Incubation, Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Staining

a Images of splinted db/db mouse wounds at day 10 post wounding. b Quantification of migrating epithelial tongues from splinted db/db mouse wounds [Error bars correspond to standard deviations from 4 biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. c IHC staining and d quantification of CD31 + cells/mm 2 demonstrating increased number blood vessels with HβCD + EGF treatment [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired student t -test, **** p < 0.0001] (E-epidermis, D-dermis; scale bar = 50 µm). d ELISA demonstrating increased levels of VEGF in splinted db/db mouse wounds upon incorporation of growth factors into HβCD hydrogels [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. (scale bar = 50 µm).

Journal: NPJ Regenerative Medicine

Article Title: Scaffolds with spatiotemporally controlled growth factor delivery and cyclodextrin-enabled antagonism of growth factor receptor sequestration promote cutaneous wound healing

doi: 10.1038/s41536-025-00431-0

Figure Lengend Snippet: a Images of splinted db/db mouse wounds at day 10 post wounding. b Quantification of migrating epithelial tongues from splinted db/db mouse wounds [Error bars correspond to standard deviations from 4 biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. c IHC staining and d quantification of CD31 + cells/mm 2 demonstrating increased number blood vessels with HβCD + EGF treatment [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired student t -test, **** p < 0.0001] (E-epidermis, D-dermis; scale bar = 50 µm). d ELISA demonstrating increased levels of VEGF in splinted db/db mouse wounds upon incorporation of growth factors into HβCD hydrogels [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. (scale bar = 50 µm).

Article Snippet: For determination of growth factor release from the hydrogels, gelatin hydrogels were loaded onto 0.4 μm PET membranes within a 24 well plate, submerged in PBS, and growth factor release quantified at 0, 12, 24, 48, 96 and 120 h using respective Quantikine ELISA kits (R&D Systems, DEG00 for EGF, DBB00 for PDGF-BB, and DVE00 for VEGF).

Techniques: Comparison, Immunohistochemistry, Enzyme-linked Immunosorbent Assay

Review

egf (R&D Systems)

Structured Review

Images

Related Articles

Enzyme-linked Immunosorbent Assay:

Diffusion-based Assay:

Concentration Assay:

Similar Products

Image Search Results